Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Currently, immune checkpoint inhibitors are achieving significant breakthroughs in adjuvant melanoma therapy. This study aims to evaluate the efficacy and safety of sintilimab combined with chemotherapy versus chemotherapy alone in patients with PD-L1-positive, completely resectable mucosal melanoma, thereby providing additional clinical evidence

Trial Details

NCT ID
NCT07400302
Phase
PHASE2
Sponsor
The First Hospital of Jilin University
Status
RECRUITING
Cancer Type
Mucosal Melanoma Melanoma
Interventions
  • Sintilimab
  • Dacarbazine or Temozolomide
  • Cisplatin
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the p…
  • Histologically/cytologically confirmed mucosal melanoma, with primary and/or metastatic lesions completely resected, with negative surgical margins.
  • Tissue specimen: PD-L1 positive (CPS ≥ 1).
  • The first dose of the study drug must be administered only after the melanoma resection wound has fully healed, and the injection time must not exc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mucosal Melanoma Melanoma Trials on Trialify →